[go: up one dir, main page]

FR2899588B1 - Utilisation de compose c-glycoside derive de galactose comme agent activateur et regulateur de l'immunite cutanee - Google Patents

Utilisation de compose c-glycoside derive de galactose comme agent activateur et regulateur de l'immunite cutanee

Info

Publication number
FR2899588B1
FR2899588B1 FR0651273A FR0651273A FR2899588B1 FR 2899588 B1 FR2899588 B1 FR 2899588B1 FR 0651273 A FR0651273 A FR 0651273A FR 0651273 A FR0651273 A FR 0651273A FR 2899588 B1 FR2899588 B1 FR 2899588B1
Authority
FR
France
Prior art keywords
galactose
activator
regulator
derived
glycoside compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0651273A
Other languages
English (en)
Other versions
FR2899588A1 (fr
Inventor
Nathalie Pineau
Maria Dalko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0651273A priority Critical patent/FR2899588B1/fr
Application filed by LOreal SA filed Critical LOreal SA
Priority to PCT/EP2007/053360 priority patent/WO2007116013A1/fr
Priority to EP07727828.1A priority patent/EP2007746B1/fr
Priority to US12/296,310 priority patent/US20090305997A1/en
Priority to ES07727828.1T priority patent/ES2605026T3/es
Priority to CNA2007800122134A priority patent/CN101415699A/zh
Priority to CN201610168876.6A priority patent/CN105748312A/zh
Publication of FR2899588A1 publication Critical patent/FR2899588A1/fr
Application granted granted Critical
Publication of FR2899588B1 publication Critical patent/FR2899588B1/fr
Priority to US14/183,205 priority patent/US20140220081A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
FR0651273A 2006-04-07 2006-04-07 Utilisation de compose c-glycoside derive de galactose comme agent activateur et regulateur de l'immunite cutanee Expired - Fee Related FR2899588B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR0651273A FR2899588B1 (fr) 2006-04-07 2006-04-07 Utilisation de compose c-glycoside derive de galactose comme agent activateur et regulateur de l'immunite cutanee
EP07727828.1A EP2007746B1 (fr) 2006-04-07 2007-04-05 Utilisation d'un composé c-glycoside dérivé du galactose en tant qu'agent pour activer et réguler l'immunité cutanée
US12/296,310 US20090305997A1 (en) 2006-04-07 2007-04-05 Use of a galactose-derived c-glycoside compound as an agent for activating and regulating cutaneous immunity
ES07727828.1T ES2605026T3 (es) 2006-04-07 2007-04-05 Uso de un compuesto de C-glicósido derivado de galactosa como agente para activar y regular la inmunidad cutánea
PCT/EP2007/053360 WO2007116013A1 (fr) 2006-04-07 2007-04-05 Utilisation d'un composé c-glycoside dérivé du galactose en tant qu'agent pour activer et réguler l'immunité cutanée
CNA2007800122134A CN101415699A (zh) 2006-04-07 2007-04-05 半乳糖衍生的c-糖苷化合物作为用于活化和调节皮肤免疫性的试剂的应用
CN201610168876.6A CN105748312A (zh) 2006-04-07 2007-04-05 半乳糖衍生的c-糖苷化合物及其组合物和应用
US14/183,205 US20140220081A1 (en) 2006-04-07 2014-02-18 Use of a galactose-derived c-glycoside compound as an agent for activating and regulating cutaneous immunity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0651273A FR2899588B1 (fr) 2006-04-07 2006-04-07 Utilisation de compose c-glycoside derive de galactose comme agent activateur et regulateur de l'immunite cutanee

Publications (2)

Publication Number Publication Date
FR2899588A1 FR2899588A1 (fr) 2007-10-12
FR2899588B1 true FR2899588B1 (fr) 2009-02-27

Family

ID=37487596

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0651273A Expired - Fee Related FR2899588B1 (fr) 2006-04-07 2006-04-07 Utilisation de compose c-glycoside derive de galactose comme agent activateur et regulateur de l'immunite cutanee

Country Status (6)

Country Link
US (2) US20090305997A1 (fr)
EP (1) EP2007746B1 (fr)
CN (2) CN105748312A (fr)
ES (1) ES2605026T3 (fr)
FR (1) FR2899588B1 (fr)
WO (1) WO2007116013A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2939677B1 (fr) * 2008-12-16 2011-06-10 Oreal Utilisation de derives c-glycosides comme agents anti-adhesion microbienne
FR2951377B1 (fr) * 2009-10-21 2012-06-22 Oreal Association d'un lysat de probiotique et d'un derive c-glycoside
FR2961511A1 (fr) * 2010-06-16 2011-12-23 Oreal C-glycosides aromatiques antioxydants cosmetiques
JP2014505058A (ja) * 2011-01-11 2014-02-27 ザ・ユニバーシティ・オブ・テキサス・エム・ディー・アンダーソン・キャンサー 増殖性および炎症性皮膚疾患の治療用単糖ベース化合物
EP3939595A1 (fr) 2013-04-05 2022-01-19 Board of Regents, The University of Texas System Esters de 2-désoxy-monosaccharides ayant une activité antiproliférative
KR102282246B1 (ko) * 2020-10-27 2021-07-27 쿼럼바이오 주식회사 갈락토스를 함유하는 아토피 피부염의 예방, 개선, 또는 치료용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6424561B1 (en) * 2000-07-18 2002-07-23 Micron Technology, Inc. MRAM architecture using offset bits for increased write selectivity
DE10138935B4 (de) * 2000-08-11 2007-08-02 Kotobuki Pharmaceutical Co., Ltd, , Hanishina Synthetische Verbindungen vom Nicht-Mucintyp oder ihre mit einem Träger konjugierten Verbindungen, unter deren Verwendung hergestellte monoclonale Antikörper, diese umfassende Antitumormittel Immunstimulantien und Mittel gegen das humane Immundefizienzvirus
FR2818646B1 (fr) * 2000-12-22 2006-06-23 Oreal Nouveaux derives c-glycoside et utilisation
FR2818547B1 (fr) * 2000-12-22 2006-11-17 Oreal Nouveaux derives c-glycosides et utilisation
WO2004094445A1 (fr) * 2003-04-18 2004-11-04 Iowa State University Research Foundation, Inc Analogue de l'isopropylthio-galactoside plus stable pour induction de l'expression proteique

Also Published As

Publication number Publication date
US20140220081A1 (en) 2014-08-07
CN101415699A (zh) 2009-04-22
EP2007746B1 (fr) 2016-08-31
ES2605026T3 (es) 2017-03-10
FR2899588A1 (fr) 2007-10-12
US20090305997A1 (en) 2009-12-10
WO2007116013A1 (fr) 2007-10-18
EP2007746A1 (fr) 2008-12-31
CN105748312A (zh) 2016-07-13

Similar Documents

Publication Publication Date Title
EP2150131A4 (fr) Composition d'application externe pour la peau contenant des extraits de baie de ginseng
EP2187742A4 (fr) Dérivés de benzylbenzène et procédés d'utilisation
MA28802B1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
PL1736160T3 (pl) Oligosacharydy alginianowe i ich pochodne oraz ich wytwarzanie i zastosowanie
FR2958542B1 (fr) Utilisation cosmetique de l'oridonine comme agent amincissant
EP2061476A4 (fr) Compositions contenant de la cdp-choline et procédés d'utilisation de celles-ci
WO2009085889A3 (fr) Compositions et procédés pour réduire ou empêcher la perte d'eau par la peau
WO2008018045A3 (fr) composition de soins personnels
BRPI0719497A2 (pt) "composição, processo de preparação de uma composição, usos de uma composição e uso coméstico de uma composição"
TWI366469B (en) Emulsified skin agent for external use
EP2237727A4 (fr) Ecarteur de tissus et methode d'utilisation associee
WO2009022077A3 (fr) Utilisation d'hespéridine ou de l'un de ses dérivés pour la prévention et/ou le traitement des peaux relâchées
FR2929509B1 (fr) L'utilisation de glycosides d'alkyle ou de melanges de glycosides d'alkyle en tant qu'agents destines a inhiber la croissance microbienne, et compositions contenant lesdits glycosides d'alkyle.
ATE548019T1 (de) Hautaufhellende mittel, zusammensetzungen und verfahren
WO2008069910A3 (fr) Lotion hydratante auto-chauffante contenue dans un flacon à double compartiment
FR2899588B1 (fr) Utilisation de compose c-glycoside derive de galactose comme agent activateur et regulateur de l'immunite cutanee
PL2231104T3 (pl) Kompozycje do higieny osobistej zawierające środki do pielęgnacji skóry
FR2899464B1 (fr) Compose c-glycoside et utilisation comme agent activateur et regulateur de l'immunite cutanee
EP1837382A4 (fr) Composition d'agent de revetement et utilisation de la composition
FR2899467B1 (fr) Utilisation de derive c-glycosides comme agent protecteur et/ou activateur des lymphocytes gamma delta t
FR2899587B1 (fr) Utilisation de compose c-glycoside derive de lactose comme agent activateur et regulateur de l'immunite cutanee
FR2899466B1 (fr) Utilisation de compose c-glycoside agent activateur et regulateur de l'immunite cutanee
FR2899474B1 (fr) Utilisation de compose c-glycoside derive d- et l-fucose comme agent activateur et regulateur de l'imminite cutanee
HU0401422D0 (en) Use of l-arginine as vasoaktive ingredient absorbing through skin for external application
FR2899463B1 (fr) Utilisation dej compose c-glycoside comme agent activateur et regulateur de l'immunite cutanee

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

ST Notification of lapse

Effective date: 20241205